Gwendolyn Wu
ReporterGwendolyn is a reporter at BioPharma Dive covering biotech startups, venture capital and the ecosystem that supports them. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn co-directs the AAJA Young Professionals Network, and teaches at the California Scholastic Press Association summer workshop. She has degrees in history and sociology from the University of California at Santa Barbara.
68 articles by Gwendolyn Wu
-
After an ‘amazing year,’ SR One raises $600M to fuel more drug startups
March 27, 2023 -
Biotech startups face ‘Series A cliff’ as venture capital stays cautious
March 24, 2023 -
At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders
March 22, 2023 -
With focus on fibrosis, startup Mediar draws big pharma backing
March 15, 2023 -
SVB’s failure was contained. Its effects on biotech could still linger.
March 14, 2023 -
Switch Therapeutics launches with $52M to capitalize on RNA medicine ‘era’
March 14, 2023 -
Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug
March 9, 2023 -
Flagship’s latest startup emerges with a plan for ‘smarter biologics’
March 7, 2023 -
GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins
March 7, 2023 -
Amid industry turbulence, Chroma raises fresh funding to edit the epigenome
March 1, 2023 -
Biotech veteran Jodie Morrison on building drug ‘platforms’ and a support group for CEOs
Feb. 21, 2023 -
With Aera, CRISPR pioneer Feng Zhang goes after gene therapy’s delivery problem
Feb. 16, 2023 -
A new generation of biotech leaders is emerging. Can they change how drug startups are built?
Feb. 14, 2023 -
Another biotech IPO hits the market, as Mineralys raises $192M
Feb. 9, 2023 -
Magenta to explore sale, merger after study setback
Feb. 3, 2023 -
Biotech startup Structure pulls off rare IPO, raising $161M
Feb. 2, 2023 -
A startup launches with plans to open up a gene and cell therapy bottleneck
Jan. 31, 2023 -
Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
Jan. 24, 2023 -
JPM23: Takeda tests Bristol Myers, Prime weighs spinoffs and Sanofi faces down a competitor
Jan. 11, 2023 -
JPM23: Califf on accelerated approvals, biotech startups’ looming cliff and an explanation from Editas
Jan. 10, 2023 -
5 questions facing emerging biotech in 2023
Jan. 10, 2023 -
Sesen, Carisma merger plans draw shareholder opposition
Jan. 4, 2023 -
Belharra debuts with $130M in funding, Genentech partnership
Jan. 4, 2023 -
FDA halts planned trial of Entrada Duchenne drug
Dec. 20, 2022 -
A San Diego startup sees covalent biologics as the next frontier in cancer drugs
Dec. 15, 2022